Baxter International Inc
Baxter International Inc (BAX) Covered Calls
As of September 28, 2026, BAX has 65 covered call opportunities in the coming three months. Return ranges from 0.9 to 73.3% until expiration. Annualized return ranges from 12.6 to 435.1%. The nearest expiration is September 25, 2026. Maximum potential profit is $1,721.
Read more
Running BAX covered calls helps you generate consistent income from Baxter International Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Baxter International Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best BAX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if BAX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling BAX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Baxter International Inc covered call is worth writing.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Income-focused investors, long-term BAX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling BAX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Baxter International Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryMedical Instruments & Supplies
- SectorHealthcare
- IV percentile89.29% Elevated
- Market cap (M$)12,144
- 52 weeks high-21.70%
- 52 weeks low49.33%
- Analyst recommendationHold
2.67 - Target price$27.60
18.63% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-10-29
- P/E—
- Future P/E11.51
- EPS (ttm)-1.93
- EPS growth next 5 years-0.67%
As of September 28, 2026
| 2026-09-25 | 2 | 24.00 | 2.17 | 0.05 | 0.20 | 56.00 | 2.38 | 435.08 | -0.21 | +0.27 | 293 | 0.15 |
| 2026-12-18 | 86 | 32.50 | 38.36 | 0.05 | 0.30 | 906.00 | 38.57 | 163.70 | -0.21 | +0.08 | 307 | 0.25 |
| 2026-09-25 | 2 | 23.50 | 0.04 | 0.20 | 0.70 | 21.00 | 0.89 | 163.15 | -0.85 | +0.51 | 20 | 0.50 |
| 2026-10-30 | 37 | 27.00 | 14.94 | 0.20 | 1.55 | 371.00 | 15.79 | 155.81 | -0.85 | +0.30 | 9 | 1.35 |
| 2026-10-09 | 16 | 25.00 | 6.43 | 0.05 | 0.40 | 156.00 | 6.64 | 151.50 | -0.21 | +0.23 | 52 | 0.35 |
| 2026-10-23 | 30 | 26.00 | 10.69 | 0.05 | 0.85 | 256.00 | 10.90 | 132.60 | -0.21 | +0.25 | 9 | 0.80 |
| 2027-01-15 | 114 | 32.50 | 38.36 | 0.10 | 0.55 | 911.00 | 38.78 | 124.17 | -0.43 | +0.13 | 818 | 0.45 |
| 2027-03-19 | 177 | 37.50 | 59.64 | 0.05 | 0.35 | 1406.00 | 59.86 | 123.43 | -0.21 | +0.07 | 20 | 0.30 |
| 2026-12-18 | 86 | 30.00 | 27.71 | 0.30 | 0.45 | 681.00 | 28.99 | 123.04 | -1.28 | +0.16 | 579 | 0.15 |
| 2026-10-30 | 37 | 26.00 | 10.69 | 0.30 | 0.95 | 281.00 | 11.96 | 118.01 | -1.28 | +0.29 | 30 | 0.65 |
As of September 28, 2026
Sell covered calls with the data behind you
Find the best BAX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→